Tocilizumab in rheumatoid arthritis: A case study of safety evaluations of a large postmarketing data set from multiple data sources
Keywords
Cited by (0)
This evaluation was funded by F. Hoffmann-La Roche Ltd. The organization was responsible for the study design in collaboration with the authors. The sponsor collected, analyzed, and interpreted the data, with the authors contributing to data interpretation and the drafting/revising of the manuscript. The authors attest to the accuracy and completeness of the reported data and had final responsibility for the decision to submit the manuscript for publication.
Susanne Pérez-Gutthann is a researcher with RTI Health Solutions, a business unit of RTI International, which receives grants from and has consultation contracts with Genentech/Roche, Iroko, and Helsinn; she also chairs the Actemra Pharmacoepidemiology Board. Samy Suissa has received fees for travel to meetings and for participation on data monitoring boards for Genentech/Roche and Bristol–Myers Squibb; he also is a researcher at McGill University, which receives grants from Boehringer-Ingelheim. Jeffrey R Curtis is a consultant to Genentech/Roche and has received grants from UCB, Janssen, CORRONA, Amgen, Pfizer, Bristol–Myers Squibb, Crescendo Biosciences, and AbbVie. Pavel Napalkov is an employee of and a stockholder in Genentech, a member of the Roche group. Natasha Singh is an employee of Genentech, a member of the Roche group. Liz Thompson is an employee of and a stockholder in Roche Products Ltd. Benjamin Porter-Brown is an employee of and a stockholder in Roche Products Ltd.